|
Table 4: Comparison of groups according to MACE. |
|||
|
Characteristics |
No MACE n (%) |
MACE n (%) |
p |
|
Age |
66.2 ± 13 |
69.5 ± 14 |
0.43 |
|
Males |
42 (49.4) |
5 (45.5) |
0.80 |
|
Smoking |
47 (54.7) |
5 (45.5) |
0.56 |
|
Diabetes mellitus |
42 (48.8) |
4 (36.4) |
0.43 |
|
Heart failure |
16 (18.6) |
1 (9.1) |
0.68 |
|
Arterial hypertension |
71 (82.6) |
9 (81.8) |
1.00 |
|
Dyslipidemia |
46 (53.5) |
9 (81.8) |
0.11 |
|
Hypothyroidism |
16 (18.6) |
1 (9.1) |
0.68 |
|
Autoimmunity |
13 (15.3) |
2 (18.2) |
0.68 |
|
Chronic kidney disease |
19 (22.1) |
2 (18.2) |
1.00 |
|
Previous CAD |
47 (54.7) |
6 (64.5) |
1.00 |
|
Family history of CAD |
34 (39.5) |
4 (36.4) |
1.00 |
|
Framingham score |
0.23 (0.12, 0.4) |
0.4 (0.18, 0.6) |
0.19 |
|
Cholesterol (mg/dL) |
165 (143, 210) |
185 (150, 195) |
0.76 |
|
LDLc (mg/dL) |
104.9 ± 38 |
96.9 ± 52 |
0.55 |
|
HDLc (mg/dL) |
46.8 ± 13 |
46.3 ± 23 |
0.92 |
|
Triglycerides |
141 (117, 185) |
172 (127, 236) |
0.24 |
|
Creatinine serum |
1 (1, 1) |
1 (1, 1) |
1.00 |
|
Beta blocker |
47 (54.7) |
6 (54.6) |
1.00 |
|
Calcium channel blocker |
22 (25.6) |
4 (36.4) |
0.47 |
|
ACEi |
20 (23.3) |
5 (45.5) |
0.14 |
|
ARB |
22 (25.6) |
3 (37.3) |
1.00 |
|
Aspirine |
40 (46.5) |
7 (63.6) |
0.28 |
|
Clopidogrel |
13 (15.1) |
5 (45.5) |
0.02 |
|
Diuretic |
18 (20.9) |
2 (18.2) |
1.00 |
|
Statins |
43 (50.0) |
6 (54.6) |
0.77 |
|
LVEF (%) |
64.8 ± 13 |
53.8 ± 18 |
0.01 |
|
Heart failure |
3 (3, 4) |
3 (2, 4) |
0.21 |
|
Mobility disturbances at rest |
29 (33.7) |
7 (63.6) |
0.09 |
|
WMA at rest |
28 (32.6) |
5 (45.5) |
0.50 |
|
Induced WMA |
26 (30.2) |
6 (54.5) |
0.17 |
|
Positive study for ischemia |
27 (31.4) |
6 (54.5) |
0.17 |
|
MACE = major adverse cardiovascular events; CAD = coronary artery disease; LDLc = low density lipoprotein cholesterol; HDLc = high density lipoprotein cholestero; ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor antagonist; LVEF = left ventricle ejection fraction; WMA = wall motion abnormalities. |
|||